10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc reduced its position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) by 44.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,277 shares of the company’s stock after selling 19,677 shares during the period. Ensign Peak Advisors Inc’s holdings in 10x Genomics were worth $692,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Wipfli Financial Advisors LLC acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $26,000. First Horizon Advisors Inc. boosted its position in shares of 10x Genomics by 64.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 476 shares during the period. Atlas Capital Advisors LLC boosted its position in shares of 10x Genomics by 45.5% in the 3rd quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company’s stock valued at $39,000 after purchasing an additional 425 shares during the period. Rockefeller Capital Management L.P. boosted its position in shares of 10x Genomics by 95.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company’s stock valued at $81,000 after purchasing an additional 1,402 shares during the period. Finally, Captrust Financial Advisors boosted its position in shares of 10x Genomics by 290.5% in the 1st quarter. Captrust Financial Advisors now owns 1,636 shares of the company’s stock valued at $124,000 after purchasing an additional 1,217 shares during the period. 74.34% of the stock is owned by institutional investors and hedge funds.

10x Genomics Price Performance

TXG opened at $47.53 on Tuesday. 10x Genomics, Inc. has a fifty-two week low of $23.81 and a fifty-two week high of $83.34. The business has a 50-day moving average of $45.82 and a 200-day moving average of $37.24. The company has a market capitalization of $5.48 billion, a PE ratio of -32.33 and a beta of 1.73.

10x Genomics (NASDAQ:TXG – Get Rating) last issued its quarterly earnings data on Wednesday, February 15th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. 10x Genomics had a negative return on equity of 20.93% and a negative net margin of 32.15%. The business had revenue of $156.20 million for the quarter, compared to the consensus estimate of $148.17 million. During the same period last year, the business earned ($0.16) EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts expect that 10x Genomics, Inc. will post -1.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TXG. Deutsche Bank Aktiengesellschaft began coverage on 10x Genomics in a research report on Tuesday, December 13th. They set a “buy” rating and a $50.00 price objective for the company. Stifel Nicolaus raised their price objective on 10x Genomics from $53.00 to $57.00 in a research report on Thursday, February 16th. UBS Group began coverage on 10x Genomics in a research report on Thursday, February 2nd. They set a “neutral” rating and a $50.00 price objective for the company. Morgan Stanley raised their price objective on 10x Genomics from $64.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday, February 16th. Finally, Canaccord Genuity Group raised their price objective on 10x Genomics from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, February 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $52.00.

Insider Activity at 10x Genomics

In related news, CEO Serge Saxonov sold 1,941 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $47.75, for a total value of $92,682.75. Following the transaction, the chief executive officer now directly owns 909,715 shares of the company’s stock, valued at approximately $43,438,891.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Serge Saxonov sold 1,941 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $47.75, for a total value of $92,682.75. Following the transaction, the chief executive officer now directly owns 909,715 shares of the company’s stock, valued at approximately $43,438,891.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 1,742 shares of 10x Genomics stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $47.75, for a total value of $83,180.50. Following the completion of the transaction, the insider now directly owns 250,237 shares in the company, valued at $11,948,816.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,928 shares of company stock valued at $235,312. Corporate insiders own 11.08% of the company’s stock.

About 10x Genomics

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.